Nichole Tucker

The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.

On the heels of promising findings from the phase 3 IMerge study, the FDA has accepted the new drug application of imetelstat for transfusion-dependent anemia in patients with lower-risk MDS.

A primary end point has been met in the phase 3 CONTACT-02 clinical trial.

A pause on trials of magrolimab in acute myeloid leukemia will affect the screening and enrollment of patients.

According to investigators of the phase 3 COLUMBUS study, BRAF/MEK inhibitor combinations are better with more BRAF inhibition.

According to Eric Jonasch, MD, promising findings from LITESPARK-005 may help with a goal of getting belzutifan FDA approval for patients with refractory renal cell carcinoma.

Data from HER2CLIMB-02 will be presented at an upcoming medical meeting and the results will be shared with the FDA.

An investigational HLA-LOH assay, xT CDx, now has the FDA's attention.

After success, preclinically and in a phase 1 dose-finding study, the phase 2 study of BDC-1001 has begun.

According to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.

In season 4, episode 12 of Targeted Talks, Federico Albrecht, MD, gives and account of 2 cases of patients with small cell lung cancer and how these patients were treated.

The first liver-directed therapy for the treatment of adult with metastatic uveal melanoma is now FDA approved.

Prior suspicions about a patient death in iMMagine-1 had been cleared up and the trial will continue with the permission of the FDA.

Findings from 2 cohorts of the phase 3 MagnetisMM-3 trial led to the FDA approval of elranatamab-bcmm for relapsed or refractory multiple myeloma treatment.

Based on the largest clinical trial of patients with HER2-amplified biliary tract cancer, a novel anti-HER bispecific antibody may be the next option.

Investigators have shared final results from the first prospective study of a BRAK/MEK inhibitor combination in patients with advanced rare cancer, including anaplastic thyroid cancer.

Results from the phase 3 MAGNITUDE study have led to a quick FDA decision on the future of a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.

For the first time ever, patients with relapsed or refractory B-cell non-Hodgkin lymphoma can receive the experimental chimeric antigen receptor T-cell therapy, CLN-978, in a clinical trial.

A phase 1/2 study marks the beginning of Genprex, Inc's clinical development of quratusugene ozeplasmid in small cell lung cancer.

Everett E. Vokes, MD, discusses the clinical application of next-generation sequencing for head and neck cancers, including thyroid cancers.

As the first study of its kind, KEYNOTE-B61 has demonstrated potential to move pembrolizumab plus lenvatinib earlier in the treatment of non-clear cell renal cell carcinoma.

The FDA has approved avasopasem for patients with head and neck cancer to treat their radiotherapy-induced severe oral mucositis.

Approval of pralsetinib for the treatment of RET fusion-positive non–small cell lung cancer in based on positive results from the phase 1/2 ARROW trial.

Early clinical trial in gastrointestinal and brain cancers aim to better understand the safety and efficacy of CEND-1-targeted therapy and develop a novel CEND-1 agent.

After more than 2 years without, the FDA has approved a companion diagnostic to identity candidates for treatment with avapritinib.

Determining the safety and efficacy of zipalertinib combined with chemotherapy for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer are the key goals of the newly-launched phase 3 REZILIENT3 study.

In an interview with Targeted Oncology, Barbara Buttin, MD, discussed important ovarian cancer research for which results were presented during the 2023 ASCO Annual Meeting.

In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.

FDA approval has been granted to dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient and microsatellite instability-high primary advanced or recurrent endometrial cancer.